表紙
市場調查報告書
商品編碼
261559

肺癌治療藥的全球市場:2019年∼2023年

Global Lung Cancer Therapeutics Market 2019-2023

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 121 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

近年來,全球肺癌治療市場出現了顯著成長,主要是由於免疫調節劑的批准日益增加。供應商使用這些療法對各種類型的癌症進行研究。市場目前只有有限數量的檢查點抑製劑,但這些藥物對全球肺癌治療市場有重大貢獻。這些藥物的高效性和日益普及預計將在預測期間為全球肺癌治療市場的成長做出重大貢獻。Technavio的分析師預測,到2023年,肺癌治療市場的年複合成長率將達到約13%。

本報告提供全球肺癌治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台

第7章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • NSCLC
  • SCLC
  • 市場機會:各類型

第8章 客戶形勢

第9章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

第15章 附錄

  • 調查方法
  • 簡稱的清單

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR31000

About this market

The global lung cancer therapeutics market has witnessed significant growth in recent years, primarily due to the increasing approval of immunomodulators. Vendors are conducting research on various types of cancer using these therapies. The market currently has only a limited number of checkpoint inhibitors, but these drugs contribute significantly to the global lung cancer therapeutics market. The high proven efficacy and the increasing popularity of these drugs are expected to contribute significantly to the growth of the global lung cancer therapeutics market during the forecast period. Technavio's analysts have predicted that the lung cancer therapeutics market will register a CAGR of about 13% by 2023.

Market Overview

Strong prevalence of lung cancer

Lung cancer is one of the most common cancer types. It is also the most common cause of cancer-related deaths globally. The new cases of cancer, especially lung cancer, have increased significantly in recent years, owing to factors such as the increasing geriatric population and lifestyle changes.

Adherence to available alternatives

The increasing advances in the diagnostic methods for lung cancer. These advances are leading to the early detection of lung cancer and are resulting in the increasing use of surgeries and radiation therapy for the treatment of the disease. This is expected to reduce the scope of therapeutics for the treatment of lung cancer, thus reducing patient adherence to lung cancer therapeutics. Thus, the increasing patient adherence to the available alternatives is expected to limit the growth of the global lung cancer therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the lung cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • NSCLC - Market size and forecast 2018-2023
  • SCLC - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global lung cancer therapeutics market pipeline: Overview
  • Exhibit 18: Global lung cancer therapeutics market pipeline: Overview
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: NSCLC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: NSCLC - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: SCLC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: SCLC - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: New cases and mortality rates of lung cancer in 2008
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 51: Bristol-Myers Squibb Company - Business segments
  • Exhibit 52: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 53: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 54: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 55: Bristol-Myers Squibb Company - Key customers
  • Exhibit 56: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 57: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 58: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 59: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 60: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 61: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 62: F. Hoffmann-La Roche Ltd - Key customers
  • Exhibit 63: Merck & Co., Inc. - Vendor overview
  • Exhibit 64: Merck & Co., Inc. - Business segments
  • Exhibit 65: Merck & Co., Inc. - Organizational developments
  • Exhibit 66: Merck & Co., Inc. - Geographic focus
  • Exhibit 67: Merck & Co., Inc. - Segment focus
  • Exhibit 68: Merck & Co., Inc. - Key offerings
  • Exhibit 69: Merck & Co., Inc. - Key customers
  • Exhibit 70: Novartis AG - Vendor overview
  • Exhibit 71: Novartis AG - Business segments
  • Exhibit 72: Novartis AG - Organizational developments
  • Exhibit 73: Novartis AG - Geographic focus
  • Exhibit 74: Novartis AG - Segment focus
  • Exhibit 75: Novartis AG - Key offerings
  • Exhibit 76: Novartis AG - Key customers
  • Exhibit 77: Pfizer Inc. - Vendor overview
  • Exhibit 78: Pfizer Inc. - Business segments
  • Exhibit 79: Pfizer Inc. - Organizational developments
  • Exhibit 80: Pfizer Inc. - Geographic focus
  • Exhibit 81: Pfizer Inc. - Segment focus
  • Exhibit 82: Pfizer Inc. - Key offerings
  • Exhibit 83: Pfizer Inc. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing